#BEGIN_DRUGCARD DB04894

# AHFS_Codes:
Not Available

# ATC_Codes:
H01CB04

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Sanvar
Sanvar IR

# CAS_Registry_Number:
103222-11-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C57H70N12O9S2

# Chemical_IUPAC_Name:
2-amino-N-[10-(4-aminobutyl)-4-{[1-carbamoyl-2-(1H-indol-2-yl)ethyl]carbamoyl}-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]-3-phenylpropanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2007-10-21 16:23:04 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied  for the treatment of cancer.

# Dosage_Forms:
Not Available

# Drug_Category:
Analgesics
Antineoplastic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
12691930	Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565.
12952505	Vapreotide: BMY 41606, RC 160, Sanvar. Drugs R D. 2003;4(5):326-30.
1354449	Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV: Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul;6(7):715-8.
16047258	Norman P: Vapreotide (Debipharm). IDrugs. 2000 Nov;3(11):1358-72.
7511473	Stiefel F, Morant R: Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer. 1993 Jan;1(1):57-8.
7909563	Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A: Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther. 1994 Apr;269(1):7-14.
7912964	Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J: Seven-day antinociceptive effect of a sustained release vapreotide formulation. Neuroreport. 1994 Jan 31;5(5):642-4.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Vapreotide

# HET_ID:
Not Available

# Half_Life:
30 minutes

# InChI_Identifier:
InChI=1S/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)28-37-26-35-14-6-8-16-41(35)62-37)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-38(70)22-20-34)53(74)66-46(27-36-29-61-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,26,29,32,40,43-49,61-62,70H,10-11,18,23-25,27-28,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73)

# InChI_Key:
InChIKey=GAWXLRUZZFSQON-UHFFFAOYSA-N

# Indication:
For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D06281

# LIMS_Drug_ID:
4894

# Mechanism_Of_Action:
The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407).

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1131.371

# Molecular_Weight_Mono:
1130.483013278

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164743146

# Pharmacology:
Vapreotide is a somatostatin analog with a higher metabolic stability than the parent hormone. Vapreotide reduces splanchnic blood flow; inhibits growth hormone release, and inhibits the release of peptides and vasoactive compounds from neuroendocrine tumors.

# Predicted_LogP_Hydrophobicity:
2.7

# Predicted_LogS:
-5.5

# Predicted_Water_Solubility:
3.99e-03 g/l

# Primary_Accession_No:
DB04894

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
23725064

# PubChem_Substance_ID:
46506923

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(CC2=CNC3=C2C=CC=C3)NC(=O)C(CC2=CC=C(O)C=C2)NC(=O)C(CSSCC(NC1=O)C(=O)NC(CC1=CC2=CC=CC=C2N1)C(N)=O)NC(=O)C(N)CC1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
BMY 41606
Octastatin
RC-160
Vapreotida [INN-Spanish]
Vapreotide acetate
Vapreotidum [inn-latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide.

# Update_Date:
2013-02-08 16:23:49 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
19708854	Fortune BE, Jackson J, Leonard J, Trotter JF: Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding. Expert Opin Pharmacother. 2009 Oct;10(14):2337-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SSTR2

# Drug_Target_1_GenBank_ID_Gene:
BC095495

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
SSTR2

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10551867	Zitzer H, Honck HH, Bachner D, Richter D, Kreienkamp HJ: Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain. J Biol Chem. 1999 Nov 12;274(46):32997-3001.
10619399	Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM: Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol. 1999 Nov 25;157(1-2):75-85.
1346068	Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5.
8386508	Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB: Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993 Apr 15;192(1):288-94.

# Drug_Target_1_HGNC_ID:
HGNC:11331

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6008

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
41333

# Drug_Target_1_Name:
Somatostatin receptor type 2

# Drug_Target_1_Number_of_Residues:
369

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Somatostatin receptor type 2
MDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIYFVVCIIGLCG
NTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLAMQVALVHWPFGKAICRVVMT
VDGINQFTSIFCLTVMSIDRYLAVVHPIKSAKWRRPRTAKMITMAVWGVSLLVILPIMIY
AGLRSNQWGRSSCTINWPGESGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGI
RVGSSKRKKSEKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVL
TYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRLNETTETQRTL
LNGDLQTSI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for somatostatins-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. In RIN-5F cells, this receptor inhibits calcium entry by suppressing voltage dependent calcium-channels

# Drug_Target_1_SwissProt_ID:
P30874

# Drug_Target_1_SwissProt_Name:
SSR2_HUMAN

# Drug_Target_1_Synonyms:
SRIF-1
SS2R

# Drug_Target_1_Theoretical_pI:
9.18

# Drug_Target_1_Transmembrane_Regions:
44-67
79-103
119-138
162-181
208-229
254-278
289-303

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
19708854	Fortune BE, Jackson J, Leonard J, Trotter JF: Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding. Expert Opin Pharmacother. 2009 Oct;10(14):2337-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SSTR5

# Drug_Target_2_GenBank_ID_Gene:
L14865

# Drug_Target_2_GenBank_ID_Protein:
431095

# Drug_Target_2_GeneCard_ID:
SSTR5

# Drug_Target_2_Gene_Name:
SSTR5

# Drug_Target_2_Gene_Sequence:
>1092 bp
ATGGAGCCCCTGTTCCCAGCCTCCACGCCCAGCTGGAACGCCTCCTCCCCGGGGGCTGCC
TCTGGAGGCGGTGACAACAGGACGCTGGTGGGGCCGGCGCCCTCGGCAGGGGCCCGGGCG
GTGCTGGTGCCCGTGCTGTACCTGCTGGTGTGTGCGGCCGGGCTGGGCGGGAACACGCTG
GTCATCTACGTGGTGCTGCGGTTCGCCAAGATGAAGACCGTCACCAACATCTACATTCTC
AACCTGGCAGTGGCCGACGTCCTGTACATGCTGGGGCTGCCTTTCCTGGCCACGCAGAAC
GCCGCGTCCTTCTGGCCCTTCGGCCCCGTCCTGTGCCGCCTGGTCATGACGCTGGACGGC
GTCAACCAGTTCACCAGTGTCTTCTGCCTGACAGTCATGAGCGTGGACCGCTACCTGGCA
GTGGTGCACCCGCTGAGCTCGGCCCGCTGGCGCCGCCCGCGTGTGGCCAAGCTGGCGAGC
GCCGCCGCCTGGGTCCTGTCTCTGTGCATGTCGCTGCCGCTCTTGGTGTTCGCGGACGTG
CAGGAGGGCGGTACCTGCAACGCCAGCTGGCCGGAGCCCGTGGGGCTGTGGGGCGCCGTC
TTCATCATCTACACGGCCGTGCTGGGCTTCTTCGCGCCGCTGCTGGTCATCTGCCTGTGC
TACCTGCTCATCGTGGTGAAGGTGAGGGCGGCGGGCGTGCGCGTGGGCTGCGTGCGGCGG
CGCTCGGAGCGGAAGGTGACGCGCATGGTGTTGGTGGTGGTGCTGGTGTTTGCGGGATGT
TGGCTGCCCTTCTTCACCGTCAACATCGTCAACCTGGCGGTTGCGCTGCCCCAGGAGCCC
GCCTCCGCCGGCCTCTACTTCTTCGTGGTCATCCTCTCCTACGCCAACAGCTGTGCCAAC
CCCGTCCTCTACGGCTTCCTCTCGGACAACTTCCGCCAGAGCTTCCAGAAGGTTCTGTGC
CTCCGCAAGGGCTCTGGTGCCAAGGACGCTGACGCCACGGAGCCGCGTCCAGACAGGATC
CGGCAGCAGCAGGAGGCCACGCGCCCGCGCACCGCCGCAGCCAACGGGCTTATGCAGACC
AGCAAGCTGTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
11157797	Daniels RJ, Peden JF, Lloyd C, Horsley SW, Clark K, Tufarelli C, Kearney L, Buckle VJ, Doggett NA, Flint J, Higgs DR: Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16. Hum Mol Genet. 2001 Feb 15;10(4):339-52.
7908405	Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB, Patel YC: Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol. 1994 Mar;45(3):417-27.
8078491	O'Carroll AM, Raynor K, Lolait SJ, Reisine T: Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol. 1994 Aug;46(2):291-8.
8373420	Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S, et al.: Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52.

# Drug_Target_2_HGNC_ID:
HGNC:11334

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3872

# Drug_Target_2_Locus:
16p13.3

# Drug_Target_2_Molecular_Weight:
39203

# Drug_Target_2_Name:
Somatostatin receptor type 5

# Drug_Target_2_Number_of_Residues:
364

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Somatostatin receptor type 5
MEPLFPASTPSWNASSPGAASGGGDNRTLVGPAPSAGARAVLVPVLYLLVCAAGLGGNTL
VIYVVLRFAKMKTVTNIYILNLAVADVLYMLGLPFLATQNAASFWPFGPVLCRLVMTLDG
VNQFTSVFCLTVMSVDRYLAVVHPLSSARWRRPRVAKLASAAAWVLSLCMSLPLLVFADV
QEGGTCNASWPEPVGLWGAVFIIYTAVLGFFAPLLVICLCYLLIVVKVRAAGVRVGCVRR
RSERKVTRMVLVVVLVFAGCWLPFFTVNIVNLAVALPQEPASAGLYFFVVILSYANSCAN
PVLYGFLSDNFRQSFQKVLCLRKGSGAKDADATEPRPDRIRQQQEATPPAHRAAANGLMQ
TSKL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase

# Drug_Target_2_SwissProt_ID:
P35346

# Drug_Target_2_SwissProt_Name:
SSR5_HUMAN

# Drug_Target_2_Synonyms:
SS5R

# Drug_Target_2_Theoretical_pI:
9.72

# Drug_Target_2_Transmembrane_Regions:
39-66
77-101
114-135
158-178
198-222
248-273
284-308

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
7556407	Betoin F, Advenier C, Fardin V, Wilcox G, Lavarenne J, Eschalier A: In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin. Eur J Pharmacol. 1995 Jun 12;279(2-3):241-9.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
TACR1

# Drug_Target_3_GenBank_ID_Gene:
S62045

# Drug_Target_3_GenBank_ID_Protein:
8176544

# Drug_Target_3_GeneCard_ID:
TACR1

# Drug_Target_3_Gene_Name:
TACR1

# Drug_Target_3_Gene_Sequence:
>1224 bp
ATGGATAACGTCCTCCCGGTGGACTCAGACCTCTCCCCAAACATCTCCACTAACACCTCG
GAACCCAATCAGTTCGTGCAACCAGCCTGGCAAATTGTCCTTTGGGCAGCTGCCTACACG
GTCATTGTGGTGACCTCTGTGGTGGGCAACGTGGTAGTGATGTGGATCATCTTAGCCCAC
AAAAGAATGAGGACAGTGACGAACTATTTTCTGGTGAACCTGGCCTTCGCGGAGGCCTCC
ATGGCTGCATTCAATACAGTGGTGAACTTCACCTATGCTGTCCACAACGAATGGTACTAC
GGCCTGTTCTACTGCAAGTTCCACAACTTCTTCCCCATCGCCGCTGTCTTCGCCAGTATC
TACTCCATGACGGCTGTGGCCTTTGATAGGTACATGGCCATCATACATCCCCTCCAGCCC
CGGCTGTCAGCCACAGCCACCAAAGTGGTCATCTGTGTCATCTGGGTCCTGGCTCTCCTG
CTGGCCTTCCCCCAGGGCTACTACTCAACCACAGAGACCATGCCCAGCAGAGTCGTGTGC
ATGATCGAATGGCCAGAGCATCCGAACAAGATTTATGAGAAAGTGTACCACATCTGTGTG
ACTGTGCTGATCTACTTCCTCCCCCTGCTGGTGATTGGCTATGCATACACCGTAGTGGGA
ATCACACTATGGGCCAGTGAGATCCCCGGGGACTCCTCTGACCGCTACCACGAGCAAGTC
TCTGCCAAGCGCAAGGTGGTCAAAATGATGATTGTCGTGGTGTGCACCTTCGCCATCTGC
TGGCTGCCCTTCCACATCTTCTTCCTCCTGCCCTACATCAACCCAGATCTCTACCTGAAG
AAGTTTATCCAGCAGGTCTACCTGGCCATCATGTGGCTGGCCATGAGCTCCACCATGTAC
AACCCCATCATCTACTGCTGCCTCAATGACAGGTTCCGTCTGGGCTTCAAGCATGCCTTC
CGGTGCTGCCCCTTCATCAGCGCCGGCGACTATGAGGGGCTGGAAATGAAATCCACCCGG
TATCTCCAGACCCAGGGCAGTGTGTACAAAGTCAGCCGCCTGGAGACCACCATCTCCACA
GTGGTGGGGGCCCACGAGGAGGAGCCAGAGGACGGCCCCAAGGCCACACCCTCGTCCCTG
GACCTGACCTCCAACTGCTCTTCACGAAGTGACTCCAAGACCATGACAGAGAGCTTCAGC
TTCTCCTCCAATGTGCTCTCCTAG

# Drug_Target_3_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_3_General_References:
1310144	Fong TM, Anderson SA, Yu H, Huang RR, Strader CD: Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol. 1992 Jan;41(1):24-30.
1312928	Takahashi K, Tanaka A, Hara M, Nakanishi S: The primary structure and gene organization of human substance P and neuromedin K receptors. Eur J Biochem. 1992 Mar 15;204(3):1025-33.
1657150	Gerard NP, Garraway LA, Eddy RL Jr, Shows TB, Iijima H, Paquet JL, Gerard C: Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry. 1991 Nov 5;30(44):10640-6.
1659396	Hopkins B, Powell SJ, Danks P, Briggs I, Graham A: Isolation and characterisation of the human lung NK-1 receptor cDNA. Biochem Biophys Res Commun. 1991 Oct 31;180(2):1110-7.
1718267	Takeda Y, Chou KB, Takeda J, Sachais BS, Krause JE: Molecular cloning, structural characterization and functional expression of the human substance P receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1232-40.
8384323	Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, Strader CD: Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature. 1993 Mar 25;362(6418):350-3.

# Drug_Target_3_HGNC_ID:
HGNC:11526

# Drug_Target_3_HPRD_ID:
01208

# Drug_Target_3_ID:
427

# Drug_Target_3_Locus:
2p13.1

# Drug_Target_3_Molecular_Weight:
46251

# Drug_Target_3_Name:
Substance-P receptor

# Drug_Target_3_Number_of_Residues:
407

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Substance-P receptor
MDNVLPVDSDLSPNISTNTSEPNQFVQPAWQIVLWAAAYTVIVVTSVVGNVVVMWIILAH
KRMRTVTNYFLVNLAFAEASMAAFNTVVNFTYAVHNEWYYGLFYCKFHNFFPIAAVFASI
YSMTAVAFDRYMAIIHPLQPRLSATATKVVICVIWVLALLLAFPQGYYSTTETMPSRVVC
MIEWPEHPNKIYEKVYHICVTVLIYFLPLLVIGYAYTVVGITLWASEIPGDSSDRYHEQV
SAKRKVVKMMIVVVCTFAICWLPFHIFFLLPYINPDLYLKKFIQQVYLAIMWLAMSSTMY
NPIIYCCLNDRFRLGFKHAFRCCPFISAGDYEGLEMKSTRYLQTQGSVYKVSRLETTIST
VVGAHEEEPEDGPKATPSSLDLTSNCSSRSDSKTMTESFSFSSNVLS

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is:substance P > substance K > neuromedin K

# Drug_Target_3_SwissProt_ID:
P25103

# Drug_Target_3_SwissProt_Name:
NK1R_HUMAN

# Drug_Target_3_Synonyms:
NK-1 receptor
NK-1R
SPR
Tachykinin receptor 1

# Drug_Target_3_Theoretical_pI:
7.22

# Drug_Target_3_Transmembrane_Regions:
32-54
65-86
107-128
149-169
195-219
249-270
284-308

#END_DRUGCARD DB04894
